Genmab A/S (GNMSF) - Grey Market
  • Aug. 30, 2012, 8:16 AM

    J&J (JNJ) unit Janssen Biotech buys the global licensing rights to cancer agent daratumumab from Danish biotech Genmab in a deal that could eventually be worth over $1.1B. Janssen is paying $55M upfront and will make further payments following the achievement of development, regulatory and sales milestones. J&J is also investing $80M in Genmab in return for a 10.7% stake. (PR)

    | Aug. 30, 2012, 8:16 AM
Company Description
Genmab is an international biotechnology company specializing in the creation and development of differentiated human antibody therapeutics for the treatment of cancer.
Sector: Technology
Industry: Biotechnology
Country: Denmark